Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24600252 | 0.95 | CREBBP (0.32) | NPBWR1MEN1KMT2A | |
| SCHEMBL29774491 | 0.87 | RXFP1 (0.33) | PDE4APDE4BPDE4CPDE4DNPBWR1 | |
| SCHEMBL24600323 | 0.85 | PPOX (0.32) | NPBWR1 | |
| SCHEMBL26643301 | 0.84 | CYP2C9 (0.37) | RXFP1MEN1KMT2A | |
| SCHEMBL26643264 | 0.80 | THRB (0.34) | NPBWR1MEN1KMT2A | |
| SCHEMBL26643283 | 0.79 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL30558175 | 0.78 | BMPR1B (0.32) | NPBWR1 | |
| SCHEMBL24600451 | 0.74 | THRB (0.31) | NPBWR1 | |
| SCHEMBL29527397 | 0.74 | NPBWR1 (0.34) | NPBWR1MEN1KMT2A | |
| SCHEMBL24600438 | 0.74 | THRB (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109863-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | KPC PHARMACEUTICALS, INC (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4273139-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | KPC Pharmaceuticals, Inc. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022143574-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 昆药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143574-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 昆药集团股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-114685450-A | 2-pyridone derivative, preparation method and medical application thereof | 昆药集团股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109863-A1 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | PTH1R, MC2R, TSHR | PDE4A 1700/4885PDE4B 889/4885PDE4C 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.